ProKidney is trading 11.62% up now at $1.58, likely reflecting biotech-sector strength rather than a company-specific announcement.
- No clear company-specific announcement emerged on August 21, 2026.
- A director’s reported sale of 757,164 shares was disclosed but does not explain the gain.
- Biotech ETF XBI rose 2.02% during regular trading, while broader indexes also advanced; the move remains momentum-driven and may reflect risk appetite rather than new clinical or financial information.